NEWS BRIEF: Legend Biotech’s revenue doubles on big gains for CAR-T treatment
Cancer treatment maker Legend Biotech Corp. (LEGN.US) reported on Friday its revenue more than doubled to $187 million in the second quarter from $73 million a year earlier, while its loss also narrowed sharply to $18 million from $199 million. Most of its revenue came from sales of Carvykti, a chimeric antigen receptor T-cell (CAR-T) therapy to treat cancer.
“Momentum for Carvykti is growing,” said Legend CEO Huang Ying, commenting on the drug that has become Legend’s primary revenue source since its approval by the FDA in the U.S. in 2022. “We look forward to starting commercial production at our Obelisc facility in Belgium later this year in order to meet the growing demand, and we remain laser-focused on increasing our manufacturing capacity.”
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK -
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
1548.HK LEGN.US
-
Legend Holdings shows diversification isn’t always a winning formula
3396.HK
-
FAST NEWS: Genscript’s new cancer drug sales surge in third quarter
1548.HK LEGN.US
-
BeiGene’s aggressive expansion brings revenue jolt
BGNE.US 6160.HK 688235.SHG
